<DOC>
	<DOCNO>NCT00926341</DOCNO>
	<brief_summary>Metabolic syndrome , label world 's late epidemic , force behind global epidemic Type 2 Diabetes Mellitus Cardio Vascular Diseases . This emerge epidemic important public health problem South Asians homeland worldwide . Pharmacological therapy critical step management patient metabolic syndrome . In general , treatment metabolic syndrome , target component metabolic syndrome either deficient non-existent . The study present pioneer work management metabolic syndrome , emerge global epidemic .</brief_summary>
	<brief_title>The Effects Peroxisome Proliferators Activated Receptor-Gamma ( PPAR-γ ) Agonists Certain Biochemical Inflammatory Markers Metabolic Syndrome</brief_title>
	<detailed_description>Our understand metabolic syndrome improve discovery nuclear peroxisome proliferator-activated receptor ( PPARs ) . PPAR-γ nuclear receptor influence expression multiple gene involve carbohydrate lipid metabolism . At crossroad obesity , insulin resistance , cardiovascular disease nuclear receptor PPAR-γ . At present , metabolic syndrome describe 'PPAR-γ agonist resistance syndrome . ' The modulation PPAR-gamma activity interest therapeutic approach address multi-component metabolic syndrome consequent cardiovascular event . Recent study indicate addition anti diabetic property , PPAR-γ agonist ( TZD ) -Pioglitazone , provide protection atherosclerotic cardiovascular disease . Further , identification ARBs-Telmisartan Irbesartan , capable activate PPAR − γ , provide novel approach treat hypertension , insulin resistance , hyperlipidemia , inflammation . Emerging evidence suggest PPAR-γ agonist : Thiazolidinediones ( TZD ) -Pioglitazone insulin sensitizer modulator metabolic syndrome , pleiotropic effect vascular risk beneficial effect systemic inflammatory marker . Despite beneficial effect full PPAR- agonist like TZDs , recent evidence suggest full PPAR- agonist less optimal agent patient metabolic syndrome . TZDs promote adipo-genesis fluid retention , cause weight gain precipitate congestive heart failure . The adverse effect full PPAR- agonist like TZDs reinforce need identify additional therapy insulin-sensitizing property . The recent discovery telmisartan , angiotensin II type 1 receptor ( AT1-R ) blocker ( ARBs ) , uniquely capable selective PPAR- -modulating activity , potential treat hemodynamic biochemical feature insulin resistance metabolic Syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients least 3 5 criterion metabolic syndrome NCEPATP III ( AsianPacific ) guideline : 1 . Waist circumference &gt; 90 cm men &gt; 80 cm woman ; 2 . Serum triglycerides &gt; = 150 mg/dl ; 3 . Highdensity lipoproteincholesterol ( HDLC ) level &lt; 40 mg/dl men &lt; 50 mg/dl woman ; 4 . Fasting glucose 6.1/ m.mol ( ≥l00 mg/dl ) 5 . Systolic blood pressure &gt; = 130 mmHg Diastolic blood pressure &gt; = 85 mmHg OR antihypertensive therapy Ability perform task related glycemic control risk factor management . Written informed consent . Between 30 70 year age either sex . Concomitant use ACE inhibitor ARB last 3 month . Or angioedema ACE I / ARB uncontrolled hypertension ( SBP &gt; =160 mmHg and/or DBP &gt; =100 mmHg ) know case secondary hypertension . Patients already take thiazolidinediones contraindication . Class III IV heart failure Renal dysfunction define serum creatinine &gt; 130umol/L ( &gt; 2.0 mg/dl ) Concomitant use statin fenofibrate . Hepatic dysfunction define SGPT ( ALT ) &gt; 3 time upper limit normal Taking Antiobesity medications/metformin History drug alcohol dependency within six month . History active malignancy , chronic , inflammatory disorder , chronic infection would interfere protocol completion . Use systemic glucocorticosteroids/aspirin/antiinflammatory drug .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Metabolic syndrome</keyword>
	<keyword>inflammatory marker</keyword>
	<keyword>Thiazolidinediones</keyword>
	<keyword>Angiotensin receptor blocker</keyword>
</DOC>